An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia
David A. Rizzieri(Duke University), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Kimberley Jackson(Eli Lilly (United Kingdom)), Xuejing Wang(University of Bern), Sarah Cooley(Palmetto Hematology Oncology), Leslie H. Brail(Eli Lilly (United States)), Lisette Moonan(Eli Lilly (United States)), Kay Hoong Chow(Eli Lilly (United Kingdom)), Olatoyosi Odenike(University of Chicago)
Cited by 78
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502